Senzime AB (SNZZF)
OTHER OTC:SNZZF
SNZZF Stock Chart & Stats
$0.54
<$0.01(0.02%)
At close: 4:00 PM EST
$0.54
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$0.35 - $0.79
Previous CloseN/A
Volume25.11K
Average Volume (3M)17.20K
Market Cap
$77.57M
Enterprise Value$671.68M
Total Cash (Recent Filing)$73.97M
Total Debt (Recent Filing)$26.40M
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Apr 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding157,215,040
10 Day Avg. Volume50,500
30 Day Avg. Volume17,200
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)2.61
Price to Sales (P/S)7.63
P/FCF Ratio-7.10
Enterprise Value/Market Cap8.66
Enterprise Value/Revenue6.46
Enterprise Value/Gross Profit20.41
Enterprise Value/Ebitda-7.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$21.06M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross Margin ImprovementMeaningful 2025 top-line expansion and a move to positive gross margins indicate improving unit economics and growing commercial traction. Durable because higher margins on disposables and platform uptake scale with installed base, supporting a path to sustainable profitability as volumes grow.
Low Leverage And Sizable Equity BaseA low debt burden and meaningful equity capital provide financial flexibility to invest in commercialization and product transitions without immediate refinancing. This structural balance-sheet strength reduces short-term refinancing risk while management executes growth initiatives.
Strong Commercial Momentum And New Service ModelHigh NextGen adoption and a placement/service model materially shorten sales cycles and lift sensor pricing, creating faster deployments and higher recurring revenue per install. These structural commercial changes improve lifetime customer value and long-term gross-margin sustainability.
Bears Say
Persistent Negative Free Cash FlowLarge and continuing free-cash-flow burn is a durable risk: losses translate into cash outflows, eroding runway and increasing the probability of future financing or dilution. Even with credit support, sustained negative FCF pressures long-term financial flexibility until operating cash generation turns positive.
Deep Unprofitability And Negative MarginsDespite revenue growth, the cost base remains well above current scale, producing outsized operating losses. Structural profitability must improve via scale, pricing or cost control; until then, returns metrics remain negative and value dilution risk persists from ongoing losses.
Placement/service Model Increases Capital IntensityOwning instruments to support a service model raises upfront CapEx and working-capital needs, increasing near-term cash strain even if margins improve later. This structural shift can slow FCF improvement and require additional funding until recurring sensor revenues scale sufficiently.
Senzime AB News
SNZZF FAQ
What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was $0.35 and its highest was $0.79 in the past 12 months.
What is Senzime AB’s market cap?
Senzime AB’s market cap is $77.57M.
When is Senzime AB’s upcoming earnings report date?
Senzime AB’s upcoming earnings report date is Apr 22, 2026 which is in 11 days.
How were Senzime AB’s earnings last quarter?
Senzime AB released its earnings results on Feb 18, 2026. The company reported -$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.029.
Is Senzime AB overvalued?
According to Wall Street analysts Senzime AB’s price is currently Overvalued.
Does Senzime AB pay dividends?
Senzime AB does not currently pay dividends.
What is Senzime AB’s EPS estimate?
Senzime AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senzime AB have?
Senzime AB has 157,215,040 shares outstanding.
What happened to Senzime AB’s price movement after its last earnings report?
Senzime AB reported an EPS of -$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Senzime AB?
Currently, no hedge funds are holding shares in SNZZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senzime AB
Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.
SNZZF Company Deck
SNZZF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents solid commercial momentum—notably strong NextGen adoption with >50% usage uplifts, geographic expansion, a SEK 50m credit facility, and a new service business model that shortens sales cycles and should improve long‑term margins. Headwinds are primarily timing and external: FX weakness reduced reported top‑line versus guidance, regulatory delays (notably Korea) postponed some revenues, and there were Q4 one‑off costs plus an inventory write‑down as the company phases out the Classic product. Management expects lower operating expenses in 2026 and to reach cash‑flow positivity in Q4 2026, indicating confidence in recovery of near‑term issues.View all SNZZF earnings summariesTechnical Analysis
Bactiguard Holding AB
―
C-Rad AB Class B
―
Integrum AB Class B
―
Sedana Medical AB
―
OssDsign AB
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
― Other Institutional Investors
99.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---